[Kangstem OSCA Phase 2a] ① Value up 4-fold… Now comes the verification of the actual contract price

Kangstem Biotech raised its global licensing target for osteoarthritis drug Oscar to about KRW 4 trillion after topline Phase 2a results.

The data showed pain and function benefits versus placebo, plus some signs of structural improvement, strengthening its partnering case.

Competitive dynamics also helped, as disappointing U.S. Phase 3 results for Kolon TissueGene’s TG-C prompted a fresh reassessment.

The company plans to share the topline and MRI data, then move through data-package review, RFP, term sheet talks, and final contract negotiations.